Inventor · disambiguated record
Najam A. Sharif
Also filed as: SHARIF NAJAM · SHARIF NAJAM A
24 granted patents·21 pending applications·176 citations·filing 1997–2020
95Inventor score
Top patents by PatentIndex Score
45 records- 0190US7867999B1Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditionsALCON RES LTD·Filed 2006·Granted Jan 11, 2011·7 cites·16 claims
- 0289US6344477B1Prostaglandin e agonists for treatment of dry eyeALCON MFG LTD·Filed 2000·Granted Feb 5, 2002·30 cites·10 claims
- 0388US7807629B1Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucomaALCON RES LTD·Filed 2008·Granted Oct 5, 2010·4 cites·8 claims
- 0488US7060704B2Serotonergic 5HT7 receptor compounds for treating ocular and CNS disordersALCON MFG LTD·Filed 2005·Granted Jun 13, 2006·5 cites·7 claims
- 0586US9604949B2Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertensionNOVARTIS AG·Filed 2015·Granted Mar 28, 2017·5 cites·12 claims
- 0686US7285553B2Serotonergic 5HT7 receptor compounds for treating ocular and CNS disordersALCON MFG LTD·Filed 2005·Granted Oct 23, 2007·4 cites·2 claims
- 0780US6664286B1Serotonergic 5ht2 agonists for treating glaucomaALCON MFG LTD·Filed 1999·Granted Dec 16, 2003·38 cites·11 claims
- 0880US6649655B211β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonistsALCON MFG LTD·Filed 2002·Granted Nov 18, 2003·11 cites·16 claims
- 0975US8263555B2Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucomaSHARIF NAJAM A·Filed 2010·Granted Sep 11, 2012·2 cites·7 claims
- 1075US7655662B2(Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressureALCON RES LTD·Filed 2006·Granted Feb 2, 2010·2 cites·6 claims
- 1171US2009203614A1Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degenerationALCON INC·Filed 2009·Application pending·0 cites
- 1270US2009181896A1Use of Natriuretic Peptide Receptor Antagonists to Treat Ocular, Otic and Nasal Edemetous ConditionsALCON RES LTD·Filed 2009·Application pending·0 cites
- 1370US2009181893A1Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balanceALCON INC·Filed 2009·Application pending·0 cites
- 1468US7718697B2Method for treating glaucoma comprising administering α-lipoic acidALCON INC·Filed 2004·Granted May 18, 2010·3 cites·1 claims
- 1565US8173668B1Use of non-peptidic bradykinin receptor agonists to treat ocular hypertension and glaucomaSHARIF NAJAM A·Filed 2008·Granted May 8, 2012·0 cites·4 claims
- 1664US2008057072A1Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disordersALCON MFG LTD·Filed 2007·Application pending·0 cites
- 1763US2006121039A1Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degenerationALCON INC·Filed 2004·Application pending·0 cites
- 1861US11331311B2Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compoundSANTEN PHARMACEUTICAL CO LTD·Filed 2020·Granted May 17, 2022·0 cites·5 claims
- 1961US6960579B1Serotonergic 5HT7 receptor compounds for treating ocular and CNS disordersALCON MFG LTD·Filed 1999·Granted Nov 1, 2005·6 cites·12 claims
- 2061US2007225225A1Use of natriuretic peptide receptor antagonists to treat ocular, otic and nasal edemetous conditionsSHARIF NAJAM A·Filed 2007·Application pending·0 cites
- 2159US6492417B111-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonistsALCON MFG LTD·Filed 1998·Granted Dec 10, 2002·22 cites·9 claims
- 2254US2005137122A1Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balanceALCON INC·Filed 2004·Application pending·0 cites
- 2353US10016441B2Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertensionNOVARTIS AG·Filed 2017·Granted Jul 10, 2018·0 cites·4 claims
- 2452US6284537B1Immortalized human corneal epithelial cell lineNESTEC SA·Filed 1997·Granted Sep 4, 2001·9 cites·5 claims
- 2551US2018200239A1Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compoundSANTEN PHARMACEUTICAL CO LTD·Filed 2016·Application pending·0 cites
- 2650US6441033B111β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonistsALCON MFG LTD·Filed 1998·Granted Aug 27, 2002·12 cites·13 claims
- 2750US2010247548A1Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disordersALCON RES LTD·Filed 2010·Application pending·0 cites
- 2850US2003203912A1Serotonergic 5HT2 agonists for treating glaucomaFiled 2003·Application pending·0 cites
- 2950US2008096238A1High throughput assay for human rho kinase activity with enhanced signal-to-noise ratioALCON INC·Filed 2007·Application pending·0 cites
- 3048US7235556B2Methods of treating dry eye disordersALCON INC·Filed 2004·Granted Jun 26, 2007·0 cites·6 claims
- 3147US6500831B1Non-peptide bradykinin receptor antagonists for use in controlling intraocular pressure and treating glaucomaALCON MFG LTD·Filed 1999·Granted Dec 31, 2002·9 cites·8 claims
- 3247US2008171719A1RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONSALCON MFG LTD·Filed 2007·Application pending·0 cites
- 3346US2009054365A1RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF OCULAR NEOVASCULARIZATIONALCON RES LTD·Filed 2008·Application pending·0 cites
- 3445US2011195962A1Use of multi-pharmacophore compounds to treat nasal disordersALCON RES LTD·Filed 2011·Application pending·0 cites
- 3544US2008214486A1RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONSALCON MFG LTD·Filed 2007·Application pending·0 cites
- 3643US2008194513A1RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF OCULAR NEOVASCULARIZATIONALCON RES LTD·Filed 2008·Application pending·0 cites
- 3742US2006115870A1High throughput assay for human Rho kinase activityALCON INC·Filed 2005·Application pending·0 cites
- 3842US2005222127A1Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balanceALCON INC·Filed 2005·Application pending·0 cites
- 3939US8252793B2Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucomaCOMBRINK KEITH D·Filed 2011·Granted Aug 28, 2012·0 cites·7 claims
- 4039US6545045B1Prostaglandin E agonists for treatment of glaucomaALCON MFG LTD·Filed 1999·Granted Apr 8, 2003·3 cites·2 claims
- 4139US2012283260A1Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucomaCOMBRINK KEITH D·Filed 2012·Application pending·0 cites
- 4237US2010173852A1USE OF AGENTS THAT DOWN-REGULATE EXPRESSION OF TANIS AND/OR P21 Waf1/Cip1/Sd1 GENES, AND USE OF AGENTS THAT INHIBIT, DEGRADE, SEQUESTER OR PREVENT THE NEUROTOXICITY OF GENE PRODUCT PROTEINS OF TANIS AND P21 Waf1/Cip1/Sd1 GENESALCON INC·Filed 2010·Application pending·0 cites
- 4335US6531480B1Non-peptide bradykinin receptor antagonists for use in treating ophthalmic diseases and disordersALCON MFG LTD·Filed 1999·Granted Mar 11, 2003·2 cites·8 claims
- 4435US6291479B1Use of NR2B-selective NMDA-receptor antagonists for the treatment of ophthalmic diseasesALCON MFG LTD·Filed 1999·Granted Sep 18, 2001·2 cites·4 claims
- 4530US2001041174A1Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseasesFiled 1999·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Najam A. Sharif files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →